Outlook Therapeutics encouraged by FDA acceptance of application for drug to treat retinal eye disease wet AMDProactive Investors • 10/28/22
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMDGlobeNewsWire • 10/28/22
Outlook Therapeutics enters into commercialization agreement with AmerisourceBergenProactive Investors • 09/27/22
Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMDGlobeNewsWire • 09/27/22
Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
Outlook Therapeutics re-submits biologics license application for ONS-5010 as a treatment for wet AMD to the FDAProactive Investors • 08/30/22
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug AdministrationGlobeNewsWire • 08/30/22
Outlook Therapeutics strengthens board with appointment of ophthalmologist Dr Julia HallerProactive Investors • 08/15/22
Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MDGlobeNewsWire • 08/15/22
Outlook Therapeutics ends 3Q with $26 million in cash and cash equivalents; plans to re-submit ONS-5010 application by SeptemberProactive Investors • 08/10/22
Outlook Therapeutics ends 3Q with $26 million in cash and cash equivalents; plans to re-submit ONS-5010 license application by SeptemberProactive Investors • 08/10/22
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term MilestonesGlobeNewsWire • 08/10/22
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology ConferenceGlobeNewsWire • 08/04/22
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory NoteGlobeNewsWire • 07/05/22
Outlook Therapeutics confirms BLA re-submission date for its ONS-5010 wet AMD treatmentProactive Investors • 06/14/22
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010GlobeNewsWire • 06/14/22
Outlook Therapeutics opts to resubmit BLA for wet AMD drug after FDA requests more infoProactive Investors • 05/31/22
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMDGlobeNewsWire • 05/31/22
Outlook Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/18/22
Outlook Therapeutics ends fiscal 2Q with $58.4M in cash as it ramps up pre-commercial activities for wet AMD treatment LytenavaProactive Investors • 05/13/22
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate UpdateGlobeNewsWire • 05/13/22
Outlook Therapeutics says its COO to talk wet AMD drug Lytenava at World Retina Conference this weekProactive Investors • 05/10/22